Reata Pharmaceuticals Inc expected to post a loss of $2.10 a share - Earnings Preview

Reata Pharmaceuticals

04/05/2021 14:48

* Reata Pharmaceuticals Inc  RETA.OQ   RETA.O  is expected to
show a fall in quarterly revenue when it reports results on May
6.
* The Plano, Texas-based company is expected to report  a
12.1% decrease in revenue to $1.189 million from $1.35 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data.​​
​* Refinitiv's mean analyst estimate for Reata Pharmaceuticals
Inc is for a loss of $2.10 per share. For the same quarter last
year, the company reported a loss of $1.47 per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months.​
* Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $234​, about 57.2% above​ its last
closing price of $100.15. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -2.15       -2.16      -1.90     Beat    11.9
 Sep. 30 2020  -1.99       -1.98      -1.94     Beat    1.9
 Jun. 30 2020  -4.07       -2.84      -1.67     Beat    41.1​
 Mar. 31 2020  -1.91       -1.98      -1.47     Beat    25.6
 Dec.          -6.05​      -5.15      -1.59     Beat    69.1​
 31​ 2019​                                              
 Sep. 30 2019  -1.27       -1.24      -1.32     Missed  -6.3​
 Jun. 30 2019  -1.12       -1.12      -1.14     Missed  -1.5
 Mar. 31 2019  -0.99       -1.00      -0.98     Beat    1.7
 This summary was machine generated May 4 at 13:48 GMT.  All
figures in US dollars unless otherwise stated